CALHM1 Antibody is affinity chromatography purified via peptide column.
Immunogen
CALHM1 antibody was raised against a 17 amino acid synthetic peptide near the amino terminus of human CALHM1. The immunogen is located within amino acids 60 - 110 of CALHM1.
CALHM1
Reaktivität: Human
WB, IF (cc), IF (p)
Wirt: Kaninchen
Polyclonal
Alexa Fluor 488
Applikationshinweise
CALHM1 antibody can be used for detection of CALHM1 by Western blot at 1 - 2 μ,g/mL. Antibody can also be used for immunohistochemistry starting at 5 μ,g/mL. For immunofluorescence start at 20 μ,g/mL.
Antibody validated: Western Blot in rat samples, Immunohistochemistry in rat samples and Immunofluorescence in rat samples. All other applications and species not yet tested.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
1 mg/mL
Buffer
CALHM1 Antibody is supplied in PBS containing 0.02 % sodium azide.
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
-20 °C,4 °C
Informationen zur Lagerung
CALHM1 antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
FAM26C antikoerper, Fam26c antikoerper, RGD1564891 antikoerper, EG546729 antikoerper, calcium homeostasis modulator 1 antikoerper, novel protein similar to vertebrate calcium homeostasis modulator protein family antikoerper, CALHM1 antikoerper, LOC557535 antikoerper, Calhm1 antikoerper
Hintergrund
CALHM1 Antibody: Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by a massive loss of neurons in several brain regions and by the presence of senile plaques comprised of aggregated amyloid-beta (Abeta) peptides produced by the endoproteolysis of the amyloid precursor protein (APP). The calcium homeostasis modulator 1 (CALHM1) is a recently identified multipass transmembrane glycoprotein that controls cytosolic Ca2+ concentration and Abeta levels. While some studies suggest CALHM1 is significantly associated with risk of AD, other reports suggest there is no link. CALHM1 has been suggested to modulate the Ca2+-dependent proteolytic process of APP through controlling the level of cytosolic Ca2+.